Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06264388 · ClinicalTrials.gov registry record · Phase 2
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2 study of High Grade Glioma and Anaplastic Astrocytoma, sponsored by Ashish Shah.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT06264388: Recruiting Phase 2 study of High Grade Glioma and Anaplastic Astrocytoma, sponsored by Ashish Shah.
NCT06264388 is a Phase 2 study of High Grade Glioma and Anaplastic Astrocytoma that is actively recruiting participants, run by Ashish Shah. The registered enrollment target is 33 participants, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06264388, a Phase 2 study of High Grade Glioma and Anaplastic Astrocytoma, is actively recruiting participants, sponsored by Ashish Shah.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.
Primary Outcome
Progression free survival (PFS) is defined as duration from initiation of treatment to the point of disease progression or death.
Conditions Studied
Interventions
- DRUG DB107-FC
- DRUG DB107-RRV
Study Locations (1)
Florida
- University of Miami Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2034-05-01 |
| Phase | Phase 2 |
What NCT06264388 shows while recruiting
NCT06264388 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 65-participant average among 42 other High Grade Glioma trials with a reported enrollment target (49% lower).
The record links to 2 conditions, with High Grade Glioma appearing as the primary indexed condition, and to 2 interventions - of which DB107-FC is the first listed.
NCT06264388 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06264388 about?
NCT06264388 is a clinical study titled "DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma". The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.
What is the current status of trial NCT06264388?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2024-05-01. Estimated completion is 2034-05-01.
What conditions does trial NCT06264388 study?
This clinical trial studies the following conditions: High Grade Glioma, Anaplastic Astrocytoma.
What interventions are being tested in trial NCT06264388?
The interventions under investigation include: DB107-FC (DRUG), DB107-RRV (DRUG).
Who is sponsoring clinical trial NCT06264388?
This trial is sponsored by Ashish Shah, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06264388 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for High Grade Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06264388's enrollment target sits among peer trials
33 20th of 42 higher than 23 of 42 other High Grade Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other High Grade Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
RECRUITING · Phase 2
-
Study of Olutasidenib and Temozolomide in HGG
RECRUITING · Phase 2
-
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
ACTIVE NOT RECRUITING · Phase 2
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI